YOUR ACTION IS NEEDED NOW! Avert a combined 9.75% cut in the Medicare physician payment system

September is a multicolored ribbon month. MOASC encourages your support of these agencies and your continued fight against: Childhood cancer, Uterine cancer, Leukemia, Lymphoma, Ovarian cancer, Prostate cancer and Thyroid cancer. Please continue to read the California Oncology Weekly and, this month, plan to attend and participate in the meetings and programs presented for you on these disease types. Thank you.

This Weekly’s Hot Topics

 

  • YOUR ACTION IS NEEDED NOW! Avert a combined 9.75% cut in the Medicare physician payment system. National News
  • TOMORROW! September 8, Enhancing Personalized Medicine in Advanced Ovarian Cancer MOASC News/ MOASC Programs
  • September 11, Hematologic Malignancies Updates: Leukemias, Lymphomas, & Myelomas 2021 ANCO News
  • September 13, comments due for CMS’ proposed rule on the Medicare Physician Fee Schedule (PFS) updates for calendar year (CY) 2022 Medicare News/CMS News
  • September 14, comments due for ICER assessment of the comparative clinical effectiveness and value of plinabulin and trilaciclib for the prevention of chemotherapy-induced neutropenia. National News

Never fight an insurance company again! Impiricus is a new platform for oncologists to access resources and get patients on therapy. Get access to grants, samples, information and more. Submit prior authorization and patient assistance requests in under 30 seconds with Impiricus’ digital interface. To read more click here and go to MOASC News.

In recognition of Ovarian Cancer Awareness Month, MOASC, in collaboration with PeerView, presents a virtual conference on Enhancing Personalized Medicine in Advanced Ovarian Cancer. Listen to expert guidance on integrating the latest updates on PARP inhibitors and novel therapeutic innovations into your clinical practice. To read more click here and go to MOASC News/MOASC Programs.

September 14, 2021, 2pm PDT is the deadline for comments to the Institute for Clinical and Economic Review (ICER) assessment of the comparative clinical effectiveness and value of plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics) for the prevention of chemotherapy-induced neutropenia. Beyond Spring Pharmaceuticals announced the submission of a New Drug Application (NDA) for plinabulin, and the FDA is expected to respond by late 2021. To read more click here and go to National News.

To read the complete California Oncology Weekly Newsletter, click on the date below.

September 7, 2021



No comments have been posted yet.